Literature DB >> 35098493

Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test.

F Bioletto1, N Prencipe2, A M Berton2, C Bona2, E Varaldo2, V Gasco2, E Ghigo2, S Grottoli2.   

Abstract

BACKGROUND: In patients with suspected acromegaly, evaluation of IGF-I is recommended as first-line test, while the assessment of GH-nadir during oral glucose tolerance test (OGTT) is advised as confirmatory test. The procedure of this test generally involves GH measurement every 30 min (30') from baseline to +120' or +180'. However, the optimal timing of samplings for the distinction between patients with or without active acromegaly is still a matter of debate.
METHODS: Sixty-seven healthy subjects and 46 acromegalic patients who achieved documented and persistent long-term cure were enrolled. A greedy algorithm was used to identify the minimal subset of time-points that sufficed to correctly detect GH suppression.
RESULTS: The sampling at 90' was the one in which a GH level < 1 μg/L was most frequently achieved (i.e., in 91.3% of cured acromegalic patients and in 91.0% of healthy subjects). Considering the whole cohort, the best combination of 2 time-points was +90' and +150' and achieved 95.6% accuracy; the best combination of 3 time-points was +60', +90' and +150' and achieved 99.1% accuracy. The minimal subset of GH determinations that demonstrated perfect accuracy (100%) needed the inclusion of 4 time-points, namely +60', +90', +120' and +150'.
CONCLUSION: A subset of 4 time-points (60' - 90' - 120' - 150') was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.
© 2021. Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Acromegaly; Acromegaly diagnosis; Growth hormone; Growth hormone suppression; Oral glucose tolerance test

Mesh:

Substances:

Year:  2022        PMID: 35098493     DOI: 10.1007/s40618-021-01731-0

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  4 in total

1.  Pituitary tumor registry: a novel clinical resource.

Authors:  M R Drange; N R Fram; V Herman-Bonert; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

Review 2.  Hormonal diagnosis of GH hypersecretory states.

Authors:  S Grottoli; V Gasco; F Ragazzoni; E Ghigo
Journal:  J Endocrinol Invest       Date:  2003       Impact factor: 4.256

3.  Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency.

Authors:  Ferenc Peter; Conrad Savoy; Hyi-Jeong Ji; Mihaly Juhasz; Martin Bidlingmaier; Paul Saenger
Journal:  Eur J Endocrinol       Date:  2008-12-12       Impact factor: 6.664

4.  Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.

Authors:  P U Freda; K D Post; J S Powell; S L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.